2,589,553 Shares in Septerna, Inc. (NASDAQ:SEPN) Acquired by Driehaus Capital Management LLC

Driehaus Capital Management LLC bought a new position in shares of Septerna, Inc. (NASDAQ:SEPN - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 2,589,553 shares of the company's stock, valued at approximately $59,301,000. Driehaus Capital Management LLC owned about 5.83% of Septerna at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. TRV GP VI LLC acquired a new position in shares of Septerna in the fourth quarter valued at $72,191,000. JPMorgan Chase & Co. bought a new stake in Septerna during the fourth quarter worth about $871,000. Corebridge Financial Inc. bought a new stake in Septerna during the fourth quarter worth about $212,000. Legal & General Group Plc bought a new stake in Septerna during the fourth quarter worth about $42,000. Finally, Barclays PLC bought a new stake in Septerna during the fourth quarter worth about $659,000.

Analysts Set New Price Targets

A number of research firms have recently commented on SEPN. Wells Fargo & Company dropped their target price on shares of Septerna from $14.00 to $11.00 and set an "equal weight" rating for the company in a report on Friday, March 28th. Cantor Fitzgerald reissued an "overweight" rating and set a $50.00 target price on shares of Septerna in a research report on Tuesday, February 11th.

Septerna Trading Up 4.3%

SEPN traded up $0.29 during trading hours on Monday, hitting $6.98. The stock had a trading volume of 217,544 shares, compared to its average volume of 410,206. The company's fifty day simple moving average is $6.18 and its 200 day simple moving average is $14.55. Septerna, Inc. has a 1 year low of $4.17 and a 1 year high of $28.99.

Septerna (NASDAQ:SEPN - Get Free Report) last posted its earnings results on Thursday, March 27th. The company reported ($0.64) earnings per share for the quarter, beating analysts' consensus estimates of ($0.69) by $0.05. The company had revenue of $0.21 million for the quarter, compared to analysts' expectations of $0.13 million. As a group, research analysts forecast that Septerna, Inc. will post -7.11 EPS for the current year.

Insider Buying and Selling at Septerna

In other news, Director Alan Ezekowitz purchased 41,355 shares of Septerna stock in a transaction that occurred on Thursday, March 6th. The shares were bought at an average cost of $6.00 per share, with a total value of $248,130.00. Following the completion of the purchase, the director now directly owns 104,101 shares in the company, valued at approximately $624,606. This trade represents a 65.91% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Gil M. Labrucherie bought 5,000 shares of the company's stock in a transaction on Friday, February 21st. The stock was bought at an average cost of $5.85 per share, for a total transaction of $29,250.00. Following the completion of the acquisition, the chief financial officer now directly owns 30,000 shares of the company's stock, valued at approximately $175,500. This represents a 20.00% increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders purchased 74,346 shares of company stock worth $439,670.

Septerna Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.